MX2024004899A - Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. - Google Patents
Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk.Info
- Publication number
- MX2024004899A MX2024004899A MX2024004899A MX2024004899A MX2024004899A MX 2024004899 A MX2024004899 A MX 2024004899A MX 2024004899 A MX2024004899 A MX 2024004899A MX 2024004899 A MX2024004899 A MX 2024004899A MX 2024004899 A MX2024004899 A MX 2024004899A
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- preventing cancer
- piperidinylpyrazine
- carboxamide compounds
- btk
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000000593 degrading effect Effects 0.000 title abstract 2
- LYWGPLOCAIBMLS-UHFFFAOYSA-N 3-piperidin-1-ylpyrazine-2-carboxamide Chemical class NC(=O)C1=NC=CN=C1N1CCCCC1 LYWGPLOCAIBMLS-UHFFFAOYSA-N 0.000 title 1
- 229940124291 BTK inhibitor Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263081P | 2021-10-26 | 2021-10-26 | |
| US202263391671P | 2022-07-22 | 2022-07-22 | |
| PCT/US2022/047767 WO2023076303A1 (en) | 2021-10-26 | 2022-10-25 | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004899A true MX2024004899A (es) | 2024-05-24 |
Family
ID=84361163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004899A MX2024004899A (es) | 2021-10-26 | 2022-10-25 | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12377106B2 (enExample) |
| EP (1) | EP4422630A1 (enExample) |
| JP (1) | JP2024542984A (enExample) |
| KR (1) | KR20240090898A (enExample) |
| AU (1) | AU2022379494A1 (enExample) |
| CA (1) | CA3236073A1 (enExample) |
| IL (1) | IL312357A (enExample) |
| MX (1) | MX2024004899A (enExample) |
| WO (1) | WO2023076303A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CA3160713A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099388A2 (en) | 2003-03-05 | 2004-11-18 | Proteologics, Inc. | Cbl-b polypeptides, complexes and related methods |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2008033403A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Agents and methods to elicit anti-tumor immune response |
| AT506041A1 (de) | 2007-12-10 | 2009-05-15 | Univ Innsbruck | Verfahren zur erhöhung der immunreaktivität |
| ES2420846T3 (es) | 2008-02-05 | 2013-08-27 | F. Hoffmann-La Roche Ag | Nuevas piridinonas y piridazinonas |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| CA3034600C (en) | 2010-05-07 | 2020-11-10 | Genentech, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| EP2471548A1 (de) | 2010-12-28 | 2012-07-04 | Apeiron Biologics AG | siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US8669251B2 (en) | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| US9499548B2 (en) | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| US10308707B2 (en) | 2013-12-02 | 2019-06-04 | Aaron Diamond Aids Research Center | Bispecific HIV-1-neutralizing antibodies |
| AU2014360446A1 (en) | 2013-12-05 | 2016-06-09 | Pharmacyclics, Llc | Inhibitors of Bruton's tyrosine kinase |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112017025986A2 (pt) | 2015-06-02 | 2018-08-14 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton. |
| CN108026088B (zh) | 2015-07-17 | 2021-02-12 | 武田药品工业株式会社 | 用作hdac抑制剂的噁二唑衍生物 |
| CN110099998A (zh) | 2016-10-26 | 2019-08-06 | 艾欧凡斯生物治疗公司 | 冷冻保存的肿瘤浸润淋巴细胞的再刺激 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3743063A4 (en) | 2018-01-26 | 2021-10-20 | Nurix Therapeutics, Inc. | CBL-B INHIBITORS AND THEIR METHODS OF USE |
| JP2021512059A (ja) | 2018-01-29 | 2021-05-13 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法 |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| EP3867242A1 (en) * | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| KR102922115B1 (ko) | 2019-04-09 | 2026-02-04 | 누릭스 테라퓨틱스 인코포레이티드 | Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도 |
| CA3140873A1 (en) | 2019-05-17 | 2020-11-26 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof |
| CA3294689A1 (en) | 2019-06-26 | 2026-03-02 | Nurix Therapeutics, Inc. | Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof |
| US12653809B2 (en) | 2019-07-30 | 2026-06-16 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition |
| EP4034141A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for expansion of immune cells |
| WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CA3160713A1 (en) * | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| IL309796A (en) | 2021-07-14 | 2024-02-01 | Nurix Therapeutics Inc | Bifunctional compounds for BTK degradation with reduced IMID activity |
| EP4373493A1 (en) | 2021-07-23 | 2024-05-29 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk with enhanced imid activity |
| MX2024004899A (es) | 2021-10-26 | 2024-05-24 | Nurix Therapeutics Inc | Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk. |
-
2022
- 2022-10-25 MX MX2024004899A patent/MX2024004899A/es unknown
- 2022-10-25 WO PCT/US2022/047767 patent/WO2023076303A1/en not_active Ceased
- 2022-10-25 CA CA3236073A patent/CA3236073A1/en active Pending
- 2022-10-25 KR KR1020247017265A patent/KR20240090898A/ko active Pending
- 2022-10-25 EP EP22809599.8A patent/EP4422630A1/en active Pending
- 2022-10-25 US US18/049,547 patent/US12377106B2/en active Active
- 2022-10-25 IL IL312357A patent/IL312357A/en unknown
- 2022-10-25 AU AU2022379494A patent/AU2022379494A1/en active Pending
- 2022-10-25 JP JP2024525065A patent/JP2024542984A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023076303A1 (en) | 2023-05-04 |
| KR20240090898A (ko) | 2024-06-21 |
| US20230149416A1 (en) | 2023-05-18 |
| CA3236073A1 (en) | 2023-05-04 |
| US12377106B2 (en) | 2025-08-05 |
| EP4422630A1 (en) | 2024-09-04 |
| AU2022379494A1 (en) | 2024-05-30 |
| IL312357A (en) | 2024-06-01 |
| JP2024542984A (ja) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| GEP20237458B (en) | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| LUC00011I2 (enExample) | ||
| TN2015000174A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| DE60026152D1 (de) | Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| NZ603952A (en) | Phosphaplatins and their use for treatment of cancers | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MA69153A1 (fr) | Méthodes de traitement d'une splénomégalie | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy | |
| SE0300098D0 (sv) | Use of cyclin D1 inhibitors | |
| BR112018005494A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. | |
| MX2022015074A (es) | Tratamiento antiviral. | |
| GB0606015D0 (en) | therapeutic agents | |
| IL191690A0 (en) | Therapy of malignant neoplasias | |
| MX2021007647A (es) | Composiciones para el cuidado bucal. | |
| ECSP077390A (es) | Uso de epotilonas en el tratamiento de metástasis en hueso y tumores o tipos de cancer en hueso | |
| ATE411014T1 (de) | Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblichem brustkrebs | |
| NO20051601L (no) | Kombinasjonsterapi med gemcitabin og zd6126 |